Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00874562 · ClinicalTrials.gov registry record · Phase 1
Rapamycin in Relapsed Acute Lymphoblastic Leukemia
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT00874562: Completed Phase 1 study, sponsored by Dana-Farber Cancer Institute.
NCT00874562 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00874562, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is a research study designed to look at the biological effects of two drugs on leukemia cells. In this study, we are comparing the effects of drugs called corticosteroids when used alone or with another drug called rapamycin. Rapamycin is a drug that prevents the body's immune system from working normally. It has been used for many years after kidney transplants to prevent rejection of the organ. Recent work suggests that rapamycin may also help treat leukemia and other cancers.
Interventions
- DRUG Corticosteroid
- DRUG Rapamycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2007-07 |
| Est. Completion | 2016-04 |
| Phase | Phase 1 |
What the finished NCT00874562 record still lists
NCT00874562 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 2 interventions - of which Corticosteroid is the first listed.
NCT00874562 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00874562 about?
NCT00874562 is a clinical study titled "Rapamycin in Relapsed Acute Lymphoblastic Leukemia". This is a research study designed to look at the biological effects of two drugs on leukemia cells. In this study, we are comparing the effects of drugs called corticosteroids when used alone or with another drug called rapamycin. Rapamycin is a drug that prevents the body's immune system from worki...
What is the current status of trial NCT00874562?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2007-07. Estimated completion is 2016-04.
What interventions are being tested in trial NCT00874562?
The interventions under investigation include: Corticosteroid (DRUG), Rapamycin (DRUG).
Who is sponsoring clinical trial NCT00874562?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00874562's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia